Literature DB >> 35942213

DRPADC: A novel drug repositioning algorithm predicting adaptive drugs for COVID-19.

Guobo Xie1, Haojie Xu1, Jianming Li1, Guosheng Gu1, Yuping Sun1, Zhiyi Lin1, Yinting Zhu1, Weiming Wang1, Youfu Wang2, Jiang Shao3.   

Abstract

Given that the usual process of developing a new vaccine or drug for COVID-19 demands significant time and funds, drug repositioning has emerged as a promising therapeutic strategy. We propose a method named DRPADC to predict novel drug-disease associations effectively from the original sparse drug-disease association adjacency matrix. Specifically, DRPADC processes the original association matrix with the WKNKN algorithm to reduce its sparsity. Furthermore, multiple types of similarity information are fused by a CKA-MKL algorithm. Finally, a compressed sensing algorithm is used to predict the potential drug-disease (virus) association scores. Experimental results show that DRPADC has superior performance than several competitive methods in terms of AUC values and case studies. DRPADC achieved the AUC value of 0.941, 0.955 and 0.876 in Fdataset, Cdataset and HDVD dataset, respectively. In addition, the conducted case studies of COVID-19 show that DRPADC can predict drug candidates accurately.
© 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COVID-19; Central kernel alignment multiple kernel learning; Compressed sensing; Drug repositioning; Weight K nearest known neighbors

Year:  2022        PMID: 35942213      PMCID: PMC9349049          DOI: 10.1016/j.compchemeng.2022.107947

Source DB:  PubMed          Journal:  Comput Chem Eng        ISSN: 0098-1354            Impact factor:   4.130


  65 in total

1.  DrugNet: network-based drug-disease prioritization by integrating heterogeneous data.

Authors:  Víctor Martínez; Carmen Navarro; Carlos Cano; Waldo Fajardo; Armando Blanco
Journal:  Artif Intell Med       Date:  2015-01-13       Impact factor: 5.326

2.  Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

Authors:  Julie Dyall; Christopher M Coleman; Brit J Hart; Thiagarajan Venkataraman; Michael R Holbrook; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Peter B Jahrling; Monique Laidlaw; Lisa M Johansen; Calli M Lear-Rooney; Pamela J Glass; Lisa E Hensley; Matthew B Frieman
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

3.  Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction.

Authors:  Zhong Li; Matthew Brecher; Yong-Qiang Deng; Jing Zhang; Srilatha Sakamuru; Binbin Liu; Ruili Huang; Cheri A Koetzner; Christina A Allen; Susan A Jones; Haiying Chen; Na-Na Zhang; Min Tian; Fengshan Gao; Qishan Lin; Nilesh Banavali; Jia Zhou; Nathan Boles; Menghang Xia; Laura D Kramer; Cheng-Feng Qin; Hongmin Li
Journal:  Cell Res       Date:  2017-07-07       Impact factor: 25.617

4.  Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.

Authors:  Koichi Watashi; Naoto Ishii; Makoto Hijikata; Daisuke Inoue; Takayuki Murata; Yusuke Miyanari; Kunitada Shimotohno
Journal:  Mol Cell       Date:  2005-07-01       Impact factor: 17.970

5.  Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B.

Authors:  J Luban; K L Bossolt; E K Franke; G V Kalpana; S P Goff
Journal:  Cell       Date:  1993-06-18       Impact factor: 41.582

6.  GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses.

Authors:  Michael K Lo; Robert Jordan; Aaron Arvey; Jawahar Sudhamsu; Punya Shrivastava-Ranjan; Anne L Hotard; Mike Flint; Laura K McMullan; Dustin Siegel; Michael O Clarke; Richard L Mackman; Hon C Hui; Michel Perron; Adrian S Ray; Tomas Cihlar; Stuart T Nichol; Christina F Spiropoulou
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

7.  SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine.

Authors:  Prabhat Pratap Singh Tomar; Isaiah T Arkin
Journal:  Biochem Biophys Res Commun       Date:  2020-06-20       Impact factor: 3.575

8.  Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.

Authors:  Ya-Nan Zhang; Qiu-Yan Zhang; Xiao-Dan Li; Jin Xiong; Shu-Qi Xiao; Zhen Wang; Zhe-Rui Zhang; Cheng-Lin Deng; Xing-Lou Yang; Hong-Ping Wei; Zhi-Ming Yuan; Han-Qing Ye; Bo Zhang
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

9.  A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs.

Authors:  Jianzhong Cao; J Craig Forrest; Xuming Zhang
Journal:  Antiviral Res       Date:  2014-11-28       Impact factor: 5.970

10.  Enabling Artificial Intelligence for Genome Sequence Analysis of COVID-19 and Alike Viruses.

Authors:  Imran Ahmed; Gwanggil Jeon
Journal:  Interdiscip Sci       Date:  2021-08-06       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.